Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Dolinger

Pediatric Gastroenterology New York, NY Medical Doctor

NPI 1043638679 CMS profile 11258998

160 E 32Nd St Fl 2, New York, NY 10016

Open in the dashboard

General payments

$190,887

114 records reported · program years 2021–2025

Research payments

$408

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Dolinger of New York, NY is reported in the CMS Open Payments database as having received $190,887 across 114 general payments and $408 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,022 33
2025 Research $408 2
2024 General $50,928 31
2023 General $72,394 29
2022 General $15,899 15
2021 General $4,644 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Dolinger
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Michael Dolinger were reported at $47,022. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Michael Dolinger Pediatric Gastroenterology median Middle half National median
2019 $0 $131 $41–$311 $163
2020 $0 $79 $23–$223 $114
2021 $4,644 $104 $32–$321 $132
2022 $15,899 $125 $37–$331 $149
2023 $72,394 $169 $55–$440 $160
2024 $50,928 $196 $73–$563 $164
2025 $47,022 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. NeuroLogica Corporation, A Subsidiary of Samsung Electronics $123,162 68 payments
  2. Pfizer Inc. $38,312 18 payments
  3. Celltrion USA Inc. $14,608 11 payments
  4. Samsung Medison Co., Ltd. $6,000 2 payments
  5. AbbVie, Inc. $4,200 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $2,505 2 payments
  7. E.R. Squibb & Sons, L.L.C. $1,419 1 payment
  8. Janssen Biotech, Inc. $535 9 payments
  9. Lilly USA, LLC $146 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $139,688 35 payments
  2. Honoraria $17,840 3 payments
  3. Travel and Lodging $16,654 20 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,200 2 payments
  5. Education $3,650 3 payments
  6. Food and Beverage $2,811 49 payments
  7. Entertainment $43 2 payments
Products named General payments · program years 2021–2025
  1. Hera W10 $102,742 48 payments
  2. HM70A $20,290 17 payments
  3. VELSIPITY $19,828 4 payments
  4. ZYMFENTRA $14,449 7 payments
  5. RS85 Prestige / IUS IBD $6,000 2 payments
  6. RINVOQ $4,200 1 payment
  7. XELJANZ $3,600 1 payment
  8. LITFULO $1,800 1 payment
  9. STELARA $313 4 payments
  10. TREMFYA $221 5 payments
  11. Other $457 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. AbbVie, Inc. $408 2 payments

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,373

Medicare's payments for the services billed

Medicare patients

40

Average age 68

Services billed

68

22 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 58%
High blood pressure 53%
Osteoporosis 33%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VELSIPITY
  • PFIZER INC. $10,200
$10,200 — —
STELARA
  • Janssen Biotech, Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record